Form 4: Sana Biotechnology Director Richard Mulligan Sells Shares

Director Richard Mulligan of Sana Biotechnology sold 300,000 shares of common stock on September 24 and 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard Mulligan, a director at Sana Biotechnology, Inc., sold 150,000 shares of common stock on September 24, 2024, at a weighted average price of $4.0838.
• The shares were sold in multiple transactions with prices ranging from $4.00 to $4.16.
• Following this transaction, Mulligan directly owns 2,848,121 shares of Sana Biotechnology.
• On September 25, 2024, Mulligan sold another 150,000 shares at a weighted average price of $3.8878, with prices ranging from $3.69 to $4.13.
• After this second transaction, Mulligan directly owns 2,698,121 shares.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 25, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a director's stock sale. It doesn't inherently convey positive or negative sentiment, but the market's reaction will depend on its interpretation of the sale.

Industry Context

Sales by insiders are a common occurrence, but significant sales can sometimes be interpreted negatively by the market, depending on the context and the size of the sale relative to the insider's holdings.

Stakeholder Impact

• Shareholders may react to the stock sale, potentially influencing the stock price.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely minimal.

Key Dates